Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Interpore's spinal implant:

This article was originally published in Clinica

Executive Summary

Interpore Cross International has received US FDA 510(k) clearance to market its implantable device for restoring biomechanical integrity of the spine following surgery for fractures or tumours in the spine. The telescopic plate spacer thoracolumbar spinal system implant is expected to be launched in the first quarter of 2002. The Irvine, California firm says that around 16,000 procedures are performed each year to remove tumours in the thoracolumbar spine, suggesting a total potential annual market of more than $60 million.

You may also be interested in...



Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Topics

UsernamePublicRestriction

Register

MT074254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel